Discover the next-gen multiple myeloma market's expansion to US$37.07 billion by 2033 with 5.4% CAGR. Key insights on monoclonal antibodies' dominance, immunomodulators like Revlimid, and RRMM applications fueled by therapies such as Elrexfio and Carvykti in relapsed settings. https://finance.yahoo.com/news/next-generation-multiple-myeloma-therapies-112000005.html